News | June 28, 2023
Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Supply readiness follows months of manufacturing to ensure timely and ample supply
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Subscribe To Our Newsletter & Stay Updated
